A Phase II Single Arm Study of Palbociclib in Patients With Metastatic HER2-positive Breast Cancer With Brain Metastasis
Latest Information Update: 06 Nov 2021
Price :
$35 *
At a glance
- Drugs Palbociclib (Primary) ; Trastuzumab
- Indications Advanced breast cancer; Brain metastases; HER2 positive breast cancer
- Focus Therapeutic Use
- 10 Feb 2020 Status changed from active, no longer recruiting to discontinued.
- 18 Feb 2019 Status changed from recruiting to active, no longer recruiting.
- 06 Jun 2017 Trial design of the study presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.